Higher expressions of CTLA4 were significantly associated with the good survival outcomes in the TCGA BRCA (Her2+) and HNSC cancer patients after adjusting for the abundances of tumor infiltrating immune cells (Figs 4 and S7). The gene discussed is CTLA4; the disease is neoplasm.